No Data
Maxim Group Maintains Rani Therapeutics(RANI.US) With Buy Rating, Maintains Target Price $15
Maxim Group analyst Michael Okunewitch maintains $Rani Therapeutics(RANI.US)$ with a buy rating, and maintains the target price at $15.According to TipRanks data, the analyst has a success rate of 26.
H.C. Wainwright Maintains Rani Therapeutics(RANI.US) With Buy Rating, Maintains Target Price $13
H.C. Wainwright analyst Mitchell Kapoor maintains $Rani Therapeutics(RANI.US)$ with a buy rating, and maintains the target price at $13.According to TipRanks data, the analyst has a success rate of 32
BTIG Maintains Rani Therapeutics(RANI.US) With Buy Rating, Maintains Target Price $14
BTIG analyst Julian Harrison maintains $Rani Therapeutics(RANI.US)$ with a buy rating, and maintains the target price at $14.According to TipRanks data, the analyst has a success rate of 47.0% and a t
Express News | Rani Therapeutics: Co, Progen to Share Responsibilities for Rt-114, Including 50/50 Cost & Revenue Share
Express News | Rani & Progen Partnership With No Upfront Payment
Express News | Rani Therapeutics & Progen Co-Develop Rt-114